SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Procept (PRCT): 50% rise on high volume. Why?
PRCT 30.42-1.1%Nov 13 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jeffers Hughes who wrote (59)3/31/1997 8:25:00 AM
From: Tracker   of 455
 
News caught my attention. Is anyone still following this stock?

CAMBRIDGE, Mass.--(BW HealthWire)--March 31, 1997-- Procept Inc announced
today that it has been issued Patent No. 5,614,559 for the use of PRO 2000 gel, a
topical microbicide it is developing as a chemical barrier to prevent HIV infection and
other STDs (sexually transmitted diseases). This patent covers claims related to a new
method of preventing HIV infection.

"Having an issued patent is an important step in the process of commercializing this
drug," said Stanley C. Erck, President and CEO of Procept. "We are working to
develop PRO 2000 as a product women can use to protect themselves against HIV and
other STDs.

Procept believes its PRO 2000 antiviral compound is well suited for development as a
female-controlled topical product to help prevent HIV infection. Laboratory studies have
shown that PRO 2000 is active against a wide range of HIV strains. It is also effective in
vitro against other STD pathogens, such as herpes simplex virus type 2, a cause of
genital lesions which are believed to be a portal of HIV entry. Easily prepared and
stable, the company believes it will be possible to manufacture sufficient quantities of
PRO 2000 to meet anticipated worldwide demand.

Clinical studies are currently underway to assess the safety of PRO 2000 in healthy
females. Based on the results of these safety studies, additional studies will be
conducted to demonstrate safety and efficacy in populations at high risk for HIV
infection.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News